@article {de Souza2020.04.25.20077396, author = {William Marciel de Souza and Lewis Fletcher Buss and Darlan da Silva Candido and Jean-Paul Carrera and Sabrina Li and Alexander E. Zarebski and Maria F. Vincenti-Gonzalez and Janey Messina and Flavia Cristina da Silva Sales and Pamela dos Santos Andrade and Carlos A. Prete, Jr and V{\'\i}tor Heloiz Nascimento and Fabio Ghilardi and Rafael Henrique Moraes Pereira and Andreza Aruska de Souza Santos and Leandro Abade and Bernardo Gutierrez and Moritz U. G. Kraemer and Renato Santana Aguiar and Neal Alexander and Philippe Mayaud and Oliver J. Brady and Izabel Oliva Marcilio de Souza and Nelson Gouveia and Guangdi Li and Adriana Tami and Silvano Barbosa de Oliveira and Victor Bertollo Gomes Porto and Fabiana Ganem and Walquiria Aparecida Ferreira de Almeida and Francieli Fontana Sutile Tardetti Fantinato and Eduardo Marques Mac{\'a}rio and Wanderson Kleber de Oliveira and Oliver G. Pybus and Chieh-Hsi Wu and Julio Croda and Ester C. Sabino and Nuno Rodrigues Faria}, title = {Epidemiological and clinical characteristics of the early phase of the COVID-19 epidemic in Brazil}, elocation-id = {2020.04.25.20077396}, year = {2020}, doi = {10.1101/2020.04.25.20077396}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The first case of COVID-19 was detected in Brazil on February 25, 2020. We report the epidemiological, demographic, and clinical findings for confirmed COVID-19 cases during the first month of the epidemic in Brazil.Methods Individual-level and aggregated COVID-19 data were analysed to investigate demographic profiles, socioeconomic drivers and age-sex structure of COVID-19 tested cases. Basic reproduction numbers (R0) were investigated for S{\~a}o Paulo and Rio de Janeiro. Multivariate logistic regression analyses were used to identify symptoms associated with confirmed cases and risk factors associated with hospitalization. Laboratory diagnosis for eight respiratory viruses were obtained for 2,429 cases.Findings By March 25, 1,468 confirmed cases were notified in Brazil, of whom 10\% (147 of 1,468) were hospitalised. Of the cases acquired locally (77{\textperiodcentered}8\%), two thirds (66{\textperiodcentered}9\% of 5,746) were confirmed in private laboratories. Overall, positive association between higher per capita income and COVID-19 diagnosis was identified. The median age of detected cases was 39 years (IQR 30-53). The median R0 was 2{\textperiodcentered}9 for S{\~a}o Paulo and Rio de Janeiro. Cardiovascular disease/hypertension were associated with hospitalization. Co-circulation of six respiratory viruses, including influenza A and B and human rhinovirus was detected in low levels.Interpretation Socioeconomic disparity determines access to SARS-CoV-2 testing in Brazil. The lower median age of infection and hospitalization compared to other countries is expected due to a younger population structure. Enhanced surveillance of respiratory pathogens across socioeconomic statuses is essential to better understand and halt SARS-CoV-2 transmission.Funding S{\~a}o Paulo Research Foundation, Medical Research Council, Wellcome Trust and Royal Society.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a FAPESP (2018/14389-0) and Medical Research Council and CADDE partnership award (MR/S0195/1). NRF is supported by a Sir Henry Dale Fellowship (204311/Z/16/Z). WMS is supported by the S{\~a}o Paulo Research Foundation, Brazil (No. 2017/13981-0). OJB was funded by a Sir Henry Wellcome Fellowship funded by the Wellcome Trust (206471/Z/17/Z). VHN and CAP were supported by FAPESP (2018/12579-7). AEZ and BG are supported by Oxford Martin School.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data mentioned in the manuscript are available.}, URL = {https://www.medrxiv.org/content/early/2020/04/29/2020.04.25.20077396}, eprint = {https://www.medrxiv.org/content/early/2020/04/29/2020.04.25.20077396.full.pdf}, journal = {medRxiv} }